AGN-190584 is a novel treatment for patients with presbyopia

Article

New eye drop is first designed to improve near vision

Data from the GEMINI 1 clinical study evaluating Allergan’s AGN-190584 for the treatment of presbyopia were presented at the American Society for Cataract and Refractive Surgery annual meeting. The new data suggests AGN-190584 could be a novel treatment for the most common and progressive form of vision loss and demonstrated that AGN-190584 met its primary and secondary efficacy endpoints.

How it works

AGN-190584 is a non-surgical treatment option that can treat presbyopia. According to the company, AGN-190584 is a potential first-of-its-kind treatment, which can affect the ability of patients with presbyopia to focus on near objects. Results from a phase 3 study showed thatAGN-190584 provided improved near vision without affecting distance vision.

“If approved by the FDA, AGN-190584 is expected to be the first eye drop specifically designed for presbyopia," said Michael Robinson, MD, vice president, global therapeutic area head, eye care, AbbVie, in a statement. "We are pleased with the favorable safety and efficacy results, as well as the rapid onset and duration of improvement in near and intermediate vision without impacting distance vision, from the Phase 3 GEMINI 1 clinical study."1

The data from the GEMINI 1 study, which was combined with those from the GEMINI 2 trial, formed the basis for the company's new drug application.

Results of the AGN-190594 trial showed that patients who were treated with AGN-190594 reported significant improvement in near-vision reading and satisfaction.

Reference

1. New data presented on the safety and efficacy of investigational AGN-190584 as a potential novel treatment for presbyopia, a common and progressive eye condition. Biospace. July 25, 2021. Accessed July 27, 2021. https://www.biospace.com/article/releases/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia-a-common-and-progressive-eye-condition/

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
© 2025 MJH Life Sciences

All rights reserved.